Artificial intelligence is moving into medicine at breakneck speed. From drafting patient notes to parsing medical journals in seconds, so-called “Doctor AI” tools promise to free up physicians’ time and turbocharge diagnostics. But behind the sleek demos and investor hype, a different kind of battle is brewing—one playing out in courtrooms, not clinics.

Recent lawsuits between companies like Doximity and OpenEvidence are exposing the messy, high-stakes fight over trade secrets, data ownership, and the very question of who controls the algorithms that may soon guide doctors’ decisions.

The outcome of these legal clashes could determine not only the business models of health-tech startups—but also the future of trust and liability in medical AI.

The Disputes: Trade Secrets, Prompt Injection, and Impersonation

In one corner: Doximity, a billion-dollar physician network best known for its LinkedIn-for-doctors platform. In the other: OpenEvidence, a rising AI startup building tools that mine medical literature and answer clinical questions in real time.

The allegations range from trade secret theft to “prompt injection” attacks—where cleverly crafted text inputs are used to manipulate an AI system. Some claims even touch on impersonation of clinicians through AI-generated content.

The specifics may sound arcane, but the stakes are massive. Whoever wins these fights could set precedents for how medical AI companies protect (or exploit) data, design safeguards, and compete in an industry where trust is everything.

Why These Lawsuits Matter

At first glance, these disputes might look like just another round of Silicon Valley mudslinging. But they cut to the heart of three defining issues for the future of healthcare AI:

1. Intellectual Property in the Age of AI

Is a medical prompt—a carefully engineered query that gets an AI to generate useful clinical insights—an intellectual asset? Can it be owned, licensed, or stolen? Courts may now have to wrestle with whether the “secret sauce” of medical AI is protectable property or just clever wording.

2. Trust and Authenticity

If AI-generated notes or answers can be impersonated or manipulated, how can doctors—or patients—trust what they see on the screen? Legal cases spotlight the urgent need for standards around authentication, watermarking, and disclosure in clinical AI.

3. Liability in the Clinic

If an AI tool misleads a doctor due to stolen code, flawed prompts, or tampered inputs, who is responsible—the doctor, the hospital, or the tech company? These lawsuits may force the industry to confront liability before patients are harmed at scale.

A Market in Flux

The legal wrangling comes at a time when the market for medical AI is exploding. Global investment in health AI is projected to hit tens of billions in the next few years. Yet the same physicians these companies are trying to serve remain cautious. Surveys show that trust, safety, and legal accountability are the top barriers to adoption.

In this light, the lawsuits are more than corporate turf wars—they’re shaping the rules of engagement for an industry that aspires to handle life-and-death decisions.

The Bigger Picture: Regulation and Oversight

While courts hash out trade secrets, regulators are circling. The FDA in the U.S. and the European Medicines Agency are working on frameworks to evaluate clinical AI tools, but the law is still catching up. The WHO has also called for stronger governance of AI in healthcare.

If private lawsuits establish new precedents faster than public regulation, we could see a patchwork of rules that make or break startups depending on which legal jurisdiction they operate in.

The Bottom Line

The promise of “Doctor AI” is dazzling: less paperwork for physicians, faster diagnoses for patients, and more efficient health systems overall. But as the courtroom battles show, trust in AI medicine won’t just be won with algorithms—it will be fought over in legal briefs and court rulings.

---

Final thought: Before AI can become a doctor’s trusted assistant, the industry will have to answer some very human questions about ownership, accountability, and ethics. The gavel, not the algorithm, may decide how the future of medical AI unfolds.